- Home
- GXAI vs XAIR Comparison
GXAI vs XAIR Comparison
Compare GXAI & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- XAIR
- Stock Information
- Founded
- GXAI 2021
- XAIR 2011
- Country
- GXAI United States
- XAIR United States
- Employees
- GXAI N/A
- XAIR N/A
- Industry
- GXAI
- XAIR Medical/Dental Instruments
- Sector
- GXAI
- XAIR Health Care
- Exchange
- GXAI Nasdaq
- XAIR Nasdaq
- Market Cap
- GXAI 19.7M
- XAIR 17.0M
- IPO Year
- GXAI 2023
- XAIR N/A
- Fundamental
- Price
- GXAI $2.08
- XAIR $2.25
- Analyst Decision
- GXAI
- XAIR Strong Buy
- Analyst Count
- GXAI 0
- XAIR 1
- Target Price
- GXAI N/A
- XAIR $11.00
- AVG Volume (30 Days)
- GXAI 14.7M
- XAIR 190.1K
- Earning Date
- GXAI 08-13-2025
- XAIR 08-12-2025
- Dividend Yield
- GXAI N/A
- XAIR N/A
- EPS Growth
- GXAI N/A
- XAIR N/A
- EPS
- GXAI N/A
- XAIR N/A
- Revenue
- GXAI $198,711.00
- XAIR $4,782,000.00
- Revenue This Year
- GXAI N/A
- XAIR $266.61
- Revenue Next Year
- GXAI N/A
- XAIR $140.76
- P/E Ratio
- GXAI N/A
- XAIR N/A
- Revenue Growth
- GXAI 72158.55
- XAIR 168.20
- 52 Week Low
- GXAI $1.00
- XAIR $2.02
- 52 Week High
- GXAI $7.50
- XAIR $13.52
- Technical
- Relative Strength Index (RSI)
- GXAI 62.20
- XAIR 35.48
- Support Level
- GXAI $1.03
- XAIR $2.02
- Resistance Level
- GXAI $2.96
- XAIR $2.42
- Average True Range (ATR)
- GXAI 0.24
- XAIR 0.20
- MACD
- GXAI 0.15
- XAIR -0.04
- Stochastic Oscillator
- GXAI 54.64
- XAIR 17.97
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.